GCT enhances European presence through a strategic acquisition in Baltic States
Princeton, NJ, USA, Nov 11, 2020
Global Clinical Trials announces the acquisition of a long-time collaborator Larrey Ltd. GCT will now offer in-house regulatory affairs, clinical monitoring, site and project management, IMP and clinical trial materials logistics and other support in Estonia, Latvia, and Lithuania.
Larrey CRO has been providing clinical research services in the Baltic States since 2011, accumulating excellent knowledge of both local market and international standards of the industry. Sergejus Krachmalis, the founder of Larrey Ltd., is appointed as the Head of GCT Baltic States and Global Clinical Lead.
Sergejus possesses rich experience in the field of clinical trials. Following his graduation from Kaunas Medical University in 2001, he worked as a lector in Vilnius Medical School. After entering clinical research, he got to be involved in all the essential parts of a drug development cycle. Sergejus will bring over 20 years of expertise as a CRA, Project Manager and Global Clinical Operations Lead. He worked with small and top 10 CROs and from the side of the sponsor companies, running regional and global studies, including those involving USA.
“It is a great honor for me to join Global Clinical Trials as Head of Baltic States. Both GCT and Larrey created long-term and fruitful relationships in the industry. I believe our mutual exchange of knowledge, global experience and regional focus will be beneficial for our Clients. It is my pleasure to be representing this region of EU and show opportunities it has to offer.”
Estonia, Latvia, and Lithuania can provide many valuable advantages to a global clinical trial. Quick clinical trial start-up is governed by the regulatory process similar to that in the EU and takes from 1 to 3 months on average. A significant incidence of oncological, cardiovascular, neurological, endocrinologic, psychiatric diseases ensures fast enrollment and patient retention. Experienced medical staff and good clinical practice (GCP) incorporated into national laws guarantee a standard of clinical research and data integrity. Import licenses are not required for IMP, laboratory kits, medical devices transport within the European Union, which makes logistics easy.
“It is a pleasure to have Sergejus and his company join us. Despite the global pandemic, we at GCT continue to put efforts in our further expansion to the most attractive countries for clinical trials. Sergejus expertise matches perfectly GCT priority therapeutic areas: oncology, genetic and rare disorders, ophthalmology, gastroenterology, reproductive health, and CNS disorders. We are thrilled with Larrey brining three new countries to GCT’s global end-to-end CRO service offerings.” said Dr. Jeffrey Apter, GCT President.
Updated: November 11, 2020
Permanent link: https://2022.gctrials.com/news/gct-enhances-european-presence-through-a-strategic-acquisition-in-baltic-states/